NEW YORK, NY -- 03/24/16 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or the “Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that members of its executive management team will attend the Sidoti Spring 2016 Emerging Growth Convention being held at the New York Marriott Marquis, New York on March 31, 2016. Sandesh Seth, Actinium’s Executive Chairman, will present an overview of the Company on Thursday, March 31, 2016 at 3:00 PM ET. A webcast of the presentation will be available through Actinium’s investor relations pagehttp://ir.actiniumpharma.com/ir-calendar.
Event: Sidoti Spring 2016 Emerging Growth Convention
Location: New York Marriott Marquis, NYC
Date: March 31, 2016
Management will be available for 1-on-1 meetings with conference attendees. To schedule a meeting please contact Steve O’Loughlin, Vice President, Finance and Corporate Development at soloughlin@actiniumpharma.com.
About the Sidoti Emerging Growth Convention
The Sidoti Spring 2016 Emerging Growth Convention will focus on companies with market capitalizations of $500 million and less, connecting their executive management teams with Wall Street’s top small- and micro-cap institutional and high-net-worth investors, research and investment banking professionals and other key stakeholders in the micro-cap investment community. Last year’s debut convention featured 55 public companies and approximately 400 attendees, including nearly 275 registered institutional investors. For more information, please refer to www.sidoti.com.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
